FluoroPharma CEO Provides Shareholders With a "State of the Union" Communication (FPMI)
FluoroPharma Medical, Inc. (OTCQB: FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.
The Company has announced the release of a company overview as presented by FluoroPharma's President, CEO and Chairman of the Board, Thijs Spoor. This second "State of the Union" address serves to provide shareholders with a perspective on the company, its evolution and future potential.
"Our company vision is clear, our financial position is sound, our promising product portfolio is on track and our company is led by a highly qualified team with significant and directly applicable experience in the successful development of radiopharmaceuticals. Our comprehensive technology platform was developed by scientists at the Massachusetts General Hospital and we are well positioned to capitalize on its superior technology.
As we advance our business model, we recognize the importance of keeping shareholders informed, and it is with this intention that I present this to you today."
The overview covers FluoroPharma's business outlook and company portfolio, including information on clinical programs and intellectual property, as well as an overview summary.
fpmi | Print Article Email Article Posted on Monday, June 18, 2012 at 4:01PM Permalink in Specialty Pharma
Reader Comments (1)
The global radiopharmaceuticals market to reach nearly $376 Million in 2021, at a CAGR of 4.9% from 2017 to 2021 - iHealthcareAnalyst, Inc. The global radiopharmaceuticals market report estimates the market size (Revenue $million - 2014 to 2021) for key market segments based on the indications (cardiovascular, oncology, neurological, thyroid, gastrointestinal, etc.), therapeutics (systemic oncology using Iodine, Yttrium, Samarium, Strontium, Rhenium, Lutetium, Erbium; cardiology, neurology, etc.), technologies (SPECT – Technetium, Thallium, Gallium, Iodine, Rhenium, Yttrium; PET - Fludeoxyglucose, Rubidium, Carbon-11 Choline, Nitrogen-13 Ammonia, etc.), generators (Mo-99/Tc-99m, Sr-82/Rb-82, Ge-68/Ga-68, Sr-90/Y-90, and W-188/Re-188 generators), end users (diagnostic centers, hospitals and medical centers), and forecasts growth trends (CAGR% - 2017 to 2021). https://www.ihealthcareanalyst.com/report/radiopharmaceuticals-market/